Want to see BSEM full AI Analyst Report?
BSEM Stock Chart & Stats
$4.01
$0.18(4.59%)
At close: 4:00 PM EDT
$4.01
$0.18(4.59%)
Day’s Range― - ―
52-Week Range$2.25 - $8.40
Previous CloseN/A
Volume31.76K
Average Volume (3M)44.17K
Market Cap
$63.13M
Enterprise Value$51.44
Total Cash (Recent Filing)$6.96M
Total Debt (Recent Filing)$1.22M
Price to Earnings (P/E)―
Beta1.90
Next Earnings
Nov 17, 2026EPS Estimate
-0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.66
Shares Outstanding17,832,811
10 Day Avg. Volume36,608
30 Day Avg. Volume44,172
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.63
Price to Sales (P/S)1.34
P/FCF Ratio9.67
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$7.00Price Target Upside74.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.95
Revenue Forecast (FY)$29.00M
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Hospital ExpansionSequential growth led by hospitals supports BioStem’s commercial shift toward larger clinical accounts. If sustained, rising hospital adoption and expanded sales coverage can improve revenue scale and create a more durable distribution base.
Commercial Infrastructure ScalingIn-house commercial processes and integrated customer systems should improve order visibility, collections and account management. Expanding direct and independent sales capacity can strengthen market reach and support repeat adoption of tissue products.
Margin Platform And Product DevelopmentA stable current margin provides an operating base, while internal manufacturing could improve economics if executed successfully. New patents, clinical data and a planned 510(k) product may also broaden differentiation and future commercialization.
Bears Say
Liquidity And Funding RiskLarge losses and cash consumption reduce financial flexibility, while the contingent payment may require financing or other liquidity measures. Continued burn could limit investment in sales, manufacturing and product development if funding is delayed.
Unstable Financial PerformanceThe sharp reversal in reported results makes the company’s underlying earnings power difficult to establish. Until revenue recognition or operating disruptions are clarified and profitability proves repeatable, forecasting and resource planning remain less reliable.
Execution-Dependent Margin RecoveryNear-term inventory effects can restrain gross margin, and the larger projected improvement relies on successful technology transfer and internal production scale-up. Delays, quality issues or insufficient volume could postpone the expected profitability benefit.
BioStem Technologies News
BSEM FAQ
What was BioStem Technologies Inc’s price range in the past 12 months?
BioStem Technologies Inc lowest stock price was $2.25 and its highest was $8.40 in the past 12 months.
What is BioStem Technologies Inc’s market cap?
BioStem Technologies Inc’s market cap is $63.13M.
When is BioStem Technologies Inc’s upcoming earnings report date?
BioStem Technologies Inc’s upcoming earnings report date is Nov 17, 2026 which is in 83 days.
How were BioStem Technologies Inc’s earnings last quarter?
BioStem Technologies Inc released its earnings results on Aug 12, 2026. The company reported -$0.52 earnings per share for the quarter, missing the consensus estimate of -$0.5 by -$0.02.
Is BioStem Technologies Inc overvalued?
According to Wall Street analysts BioStem Technologies Inc’s price is currently Undervalued.
Does BioStem Technologies Inc pay dividends?
BioStem Technologies Inc does not currently pay dividends.
What is BioStem Technologies Inc’s EPS estimate?
BioStem Technologies Inc’s EPS estimate is -0.43.
How many shares outstanding does BioStem Technologies Inc have?
BioStem Technologies Inc has 17,832,811 shares outstanding.
What happened to BioStem Technologies Inc’s price movement after its last earnings report?
BioStem Technologies Inc reported an EPS of -$0.52 in its last earnings report, missing expectations of -$0.5. Following the earnings report the stock price went down -18.421%.
Which hedge fund is a major shareholder of BioStem Technologies Inc?
Currently, no hedge funds are holding shares in BSEM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioStem Technologies Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.00 (74.56% Upside)
$7.00 (74.56% Upside)
Blogger Sentiment
Bullish
BSEM Sentiment 100%
Sector Average 61%
Sector Average 61%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 9.4%
Last 30 Days ▲ 5.0%
Last 30 Days ▲ 5.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-66.18%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-56.65%
Trailing 12-Months
Company Description
BioStem Technologies Inc
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.
BSEM Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlights strong operating execution around integration, commercial expansion, product and IP progress, sequential revenue growth (+29.5% quarter-over-quarter) and a raised revenue outlook. However, meaningful near-term financial challenges were emphasized: a $9.0 million GAAP loss, adjusted EBITDA loss, cash down to $7.0 million (≈49% decline sequentially), a $10 million contingent payment pending, and anticipated H2 margin pressure tied to legacy inventory. Management is progressing on strategic initiatives (Nasdaq uplisting, CRM/ERP integration, salesforce scale, patents, clinical data and a planned manufacturing transfer), but near-term liquidity and profitability depend on executing financing plans and the 2027 manufacturing transfer. Overall, positive operational momentum is balanced by significant near-term financial and execution risks.View all BSEM earnings summariesBSEM Stock 12 Month Forecast
Average Price Target
$7.00
▲(74.56% Upside)